Real-World Treatment Attrition in Advanced Renal Cell Carcinoma

In this segment on advanced renal cell carcinoma, Dr. Ornstein raises the important issue of real-world treatment attrition, noting that not all patients are able to receive subsequent lines of therapy after disease progression. He frames this as a key consideration when selecting first-line treatment.

Dr. Friedlander discusses how real-world outcomes often differ from clinical trial expectations, emphasizing that a substantial proportion of patients may not transition to second-line therapy. He highlights factors such as disease progression, comorbidities, and declining performance status that can limit treatment continuity. He adds that these realities reinforce the importance of maximizing benefit early in the disease course, as the greatest clinical impact is often achieved in the first-line setting. The discussion underscores the need to prioritize effective upfront therapy while acknowledging real-world challenges that influence sequencing decisions in advanced renal cell carcinoma.